BSEM (BioStem Technologies) Total Current Assets: $52.7 Mil (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.30
GF Value $141.44
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Total Current Assets?

BioStem Technologies BSEM -5.17% 49 Total Current Assets is $52.7 Mil as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $141.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioStem Technologies's total current assets for the quarter that ended in Sep. 2025 was $52.7 Mil.

BioStem Technologies  (OTCPK:BSEM) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioStem Technologies's Liquidation Value for the quarter that ended in Sep. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=27.158-12.376+0.75 * 20.105+0.5 * 2.729
=31.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Total Current Assets Related Terms

BioStem Technologies Total Current Assets Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Total Current Assets Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.94 1.49 12.60 133.76

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.80 12.60 101.38 133.76 52.69
BSEM
49GF Score
BioStem Technologies Inc BSEM
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioStem Technologies's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=22.833+106.23+1.824+2.874
=133.8

BioStem Technologies's Total Current Assets for the quarter that ended in Sep. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=27.158+20.105+2.729+2.7
=52.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $52.7 Mil mean?
BioStem Technologies (BSEM) has a Total Current Assets of $52.7 Mil as of Sep. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors.
Is BioStem Technologies' Total Current Assets too high?
BioStem Technologies' current Total Current Assets is $52.7 Mil. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Total Current Assets compare to XLO and TCRX?
BioStem Technologies' Total Current Assets of $52.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors. BioStem Technologies's current Total Current Assets is $52.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.44, compared to a current price of $3.30 — trading 97.7% below its estimated fair value. The current Total Current Assets is $52.7 Mil. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Total Current Assets is $52.7 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.30 is trading 97.7% below its estimated GF Value™ of $141.44. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Total Current Assets: $52.7 Mil
  • GF Value™: $141.44 vs. price of $3.30 (97.7% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price
$141.44
GF Value